<!DOCTYPE html>
<html>
  <head>
	<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
	<meta http-equiv="X-UA-Compatible" content="chrome=1,IE=edge" />
	<title>index</title>
	<style>
		html {
			height:100%;
		}
		body {
			background-color:#FFF;
			margin:0;
			height:100%;
		}
	</style>
	<!-- copy these lines to your document head: -->

	<meta name="viewport" content="user-scalable=yes, width=1280" />
	<style>
@font-face {
  font-family: 'FontAwesome';
  src:	url('index/fontawesome-webfont.eot?v=4.2.0');
  src:	url('index/fontawesome-webfont.eot?#iefix&v=4.2.0') format('embedded-opentype'),
  		url('index/fontawesome-webfont.woff?v=4.2.0') format('woff'),
  		url('index/fontawesome-webfont.ttf?v=4.2.0') format('truetype'),
  		url('index/fontawesome-webfont.svg?v=4.2.0#fontawesomeregular') format('svg');
  font-weight: normal;
  font-style: normal;
}
</style>
	<script type="text/javascript" src="index/behaviors.js"></script>
	<script type="text/javascript" src="index/bootstrap.min.js"></script>
	<script type="text/javascript" src="index/jquery-2.1.3.min.js"></script>
	<link rel="stylesheet" type="text/css" href="index/collapsible.css" />
	<link rel="stylesheet" type="text/css" href="index/style.css" />
	<link rel="stylesheet" type="text/css" href="index/werfen.css" />
	
	<script>


  function myCallback(hypeDocument, element, event) {
    window.myhypedocument = hypeDocument;
  }
  
  if("HYPE_eventListeners" in window === false) {
    window.HYPE_eventListeners = Array();
  }
  window.HYPE_eventListeners.push({"type":"HypeDocumentLoad", "callback":myCallback});
  
 </script>
	<script type="text/javascript" src="behaviors.js"></script>
	
	
	<style>
	
	table.wtable2
{
	width: 100%;
	text-align: left;
	border-collapse: collapse;

}
table.wtable2 caption
{
	font-weight: normal;
	font-family: "pf_square_sans_proregular";
	padding: 10px 8px;
	background: #7D98AB;
	color: #fff;
}
table.wtable2 th
{
	font-weight: normal;
	font-family: "pf_square_sans_proregular";
	padding: 10px 8px;
	background: #7D98AB;
	color: #fff;
	font-size: 16px;
	line-height: 17px;
}
table.wtable2 td
{
	padding: 10px 8px;
	color: #333;
	font-size: 16px;
	line-height: 17px;
}
table.wtable2 .odd
{
	background: #f5f5f5; 
}
	</style>
	
	<script type="text/javascript" src="behaviors.js"></script>
	<script src='index/bootstrap.min.js'></script>

	<!-- end copy -->
  </head>
  <body>
	<!-- copy these lines to your document: -->

	<div id="index_hype_container" class="HYPE_document" style="margin:auto;position:relative;width:1280px;height:720px;overflow:hidden;">
		<script type="text/javascript" charset="utf-8" src="index/index_hype_generated_script.js?33868"></script>
	</div>

	<!-- end copy -->
	


	<!-- text content for search engines: -->

	<div style="display:none" aria-hidden=true>

		<div></div>
		<div>Rotem sigma
</div>
		<div>Intelligent Quality Management (iQM®)

Active quality management program providing continuous monitoring of analytical
process, replacing traditional quality controlReal-time, automatic error detection, correction and documentation of all
corrective actionsContinuous checks—before and after every sampleSystem checksSensor checksProcess Control Solution stability checksPattern recognition checks</div>
		<div>asssss
</div>
		<div>© Instrumentation Laboratory. All rights reserved. Confidential.</div>
		<div>HomeHomecollapseOverview OverviewSimpleRapidLab-QualityGEM PAKcollapse Clinical ScenariosClinical Scenarioscollapse iQMiQMcollapse ConnectivityConnectivitycollapseToolsiQM2 Tools BrochuresGEM Premier ChemSTAT BrochureGEM Premier ChemSTAT Specification Sheet PresentationsGEM Premier ChemSTAT Promotional PPT Clinical SupportClinical Evaluation of a New Point-of-Care System for Chemistry Panel TestingcollapseRelatedROTEM sigma Related ProductsiQMGEMweb Plus 500GEM Premier 5000GEM Premier 3500</div>
		<div>OVERVIEW
</div>
		<div>Introducing</div>
		<div>GEM Premier ChemSTAT system is not available in all countries. ​</div>
		<div>Customizable connectivity and automated functionalityFor comprehensive management of analyzers, operators
and data oversight.</div>
		<div>Simplicity for Point-of-Care Testing (POCT)

Sample-type flexibility: venous and arterial Configurable assay menu Simple to operate GEM PAK saves times and reduces risk </div>
		<div>Simple to Operate—Just Press GO!

Intuitive, easy-to-use interfaceExpedites testing processReduces risk of error in test and sample-source selectionRapid time-to-results: 70 secondsJust press GO!</div>
		<div>RAPID</div>
		<div>Brandenburg, Mark A, Dire, Daniel J. Comparison of arterial and venous blood gas values in the initial emergency department evaluation of patients with diabetic ketoacidosis. Ann Emerg Med. 1998;31:4:459–65.Gokel Y, Paydas S, Koseoglu Z, et al. Comparison of blood gas and acid-base measurements in arterial and venous blood samples in patients with uremic acidosis and diabetic ketoacidosis in the emergency room. Am J Neph. 2000;20:319–23.Ma JO, Rush MD, Godfrey MM, et al. Arterial blood gas results rarely influence emergency physician management of patients with suspected diabetic ketoacidosis. Ann Emerg Med. 2003;10:836–41.Malatesha G, Singh N, Bharija A, et al. Comparison of arterial and venous pH, bicarbonate, PCO2 and PO2 in initial emergency department assessment. Emerg Med. 2007;24:569–71.Middleton P, Kelly AM, Brown J. Agreement between arterial and central venous values for pH, bicarbonate, base excess, and lactate. Emerg Med J. 2006;23:622–24.Savage MW, Datary KK, Culvert A, et al. Joint British Diabetes Societies. Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011;28(5):508–15.Lim BL, Kelly A-M. A meta-analysis on the utility of peripheral venous blood gas analyses in exacerbations of chronic obstructive pulmonary disease in the emergency department. Eur J Emerg Med. 2010;17:246–8.Younger JG, Falk JL, Rothrock SG. Relationship between arterial and peripheral venous lactate levels. Acad Emerg Med.1996;3(7):730–4.Jones AE, Leonard MM, Hernandez-Nino J, et al. Determination of the effect of in vitro time, temperature, and tourniquet use on whole blood venous point-of-care lactate concentrations. Acad Emerg Med. 2007;14:587–91.</div>
		<div>SIMPLE</div>
		<div>|</div>
		<div>GEM-PAK</div>
		<div>LAB-QUALITY</div>
		<div>Sample-Type Flexibility:Venous and Arterial

Venous samples have been demonstrated to guide treatment in the emergency department (ED)1-9</div>
		<div>National Institute of General Medical Sciences. National Institutes of Health. Sepsis fact sheet. 2014.Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Crit Care Med. 2018;46(6):997–1000.</div>
		<div>Customized Menu for the ED

Helps enable timely diagnosis in critical scenarios

Acute kidney injury (AKI) and Contrast-
induced nephropathy (CIN)Electrolytes, Crea, eGFR, BUNSepsis and septic shockElectrolytes, Lac, pH, pCO2Diabetic ketoacidosis (DKA)Glu, pH, HCO3</div>
		<div>Diabetic Ketoacidosis

Accounts for >110,000 hospitalizations in US annually, with 2–10% mortality1-3POC BMP testing allows initiation of fluid/electrolyte replacement and insulin therapy in ED, leading to improved patient outcomes4Integration of clinical findings with venous blood gas results can safely guide
management decisions5</div>
		<div>AKI and CIN

CIN is the third-leading cause of AKI in hospitalized patients with 12% incidence1Accurate testing may improve clinical decisions when balancing benefits of
radiocontrast-enhanced imaging vs. AKI risk2Rapid and accurate measurement of creatinine levels, together with eGFR values,
can help prevent CIN3</div>
		<div>Wetterhall SF, Olson DR, DeStefano F, et al. Trends in diabetes and diabetic complications, 1980–1987. Diabetes Care. 1992;15:960–7.Lebovitz HE. Diabetic ketoacidosis. Lancet. 1995;345:767–72.Bagdade JD. Endocrine emergencies. Med Clin North Am. 1986;70:1111–28.Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19(27):155–77.Kelly AM. Can VBG analysis replace ABG analysis in emergency care? Emerg Med J. 2016;33:152–4.</div>
		<div>Mohammed NMA, Mahfouz A, Achkar K, et al. Contrast-induced nephropathy. Heart Views.
2013;14:106–16.Willhem-Leen E, Montez-Rath ME, Chertow G. Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol. 2017;28(2):653–9.Faggioni M, Mehran R. Preventing contrast-induced renal failure: a guide. Interv Cardiol.
2016;11:98–104.</div>
		<div>Sepsis and Septic Shock

Claims more lives than breast cancer, prostate cancer and human immunodeficiency virus combined1Surviving Sepsis Campaign International Guidelines recommend hospitals have a performance-improvement program for sepsis, including sepsis screening for acutely ill, high-risk patients2On-demand, POC lactate testing can rapidly guide protocolized, quantitative
resuscitation and management3</div>
		<div>CONNECTIVITY
</div>
		<div>CLINICAL SCENARIOS
</div>
		<div>iQM
</div>
		<div>Soremekun OA, Datner EM, Banh S, et al. Utility of point-of-care testing in ED triage. Am J Emerg Med. 2013;31:291–6.Pines JM, Zocchi S, Buchanan ME, et al. Creating ED point-of-care testing protocols: an expert panel and Delphi process. Am J Emerg Med. 2015;33(3):463–5.Svirsky I, Stoneking LR, Grall K, et al. Resident-initiated advance triage effect on emergency
department patient flow. J Emerg Med. 2013;45:746–51.Stauber MA. Advanced nursing interventions and length of stay in the emergency department. J Emerg Nurs. 2013;39:221–5.</div>
		<div>SIMPLE</div>
		<div>Soremekun OA, Datner EM, Banh S, et al. Utility of point-of-care testing in ED triage. Am J Emerg Med. 2013;31:291–6.Pines JM, Zocchi S, Buchanan ME, et al. Creating ED point-of-care testing protocols: an expert panel and Delphi process. Am J Emerg Med. 2015;33(3):463–5.Willhem-Leen E, Montez-Rath ME, Chertow G. Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol. 2017;28(2):653–9.Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Crit Care Med. 2018;46(6):997–1000.Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018;19(27):155–77.</div>
		<div>Rapid Time-to-Results: 70 Seconds

Aids in rapid risk stratification and prioritization of high-risk, acutely ill patients1,2Enables expedited time to treatment2-5Enables improved patient management and quality of care2-5Provides critical information: Renal functionElectrolytesAcid/base balanceGlucose and Lactate</div>
		<div>Triage POC Testing (POCT)

POCT performed during ED triage has been demonstrated to: 1,2Impact modification of the Emergency Severity Index in 15% of casesResult in patient management changes in 15% of casesHelp 56% of clinicians during triageResults in 6% of patients returning for treatmentTriage POCT in the ED is a helpful adjunct for patients presenting with high-risk complaints.3,4</div>
		<div>Lab-Quality Results

Excellent Creatinine Correlation with Lab Enzymatic Method

Method Comparison1Whole-blood samples from
ED and inpatient units at
3 external sites (n=430)**Some samples were contrived to cover entire analytical measurement range</div>
		<div>Data collected during GEM Premier ChemSTAT Clinical Evaluation. On file, IL.</div>
		<div>GEM PAK</div>
		<div>GEM PAK Enhances Efficiency and Reduces Risk

Self-contained cartridge includes all testing componentsAutomates the most labor- and skill-intensive processesRoom-temperature storage; no refrigeration requiredJust replace every 21 daysIdeal for high- and low-volume testing needs with 75,
150, 300, 450-test PAK configurationsOnly one GEM PAK to inventory and manageNo liquids or biohazardous material enter analyzer; thus,
no maintenance or troubleshooting required and no
exposureNote: CVP ampoules must be run to activate the GEM PAK prior to patient testing</div>
		<div>* Two eGFR results are provided by the analyzer if the Crea result, age, gender and ethnicity are available: eGFRAA (MDRD) for African Americans (AA) and eGFR (MDRD for non-AA.
** Two eGFR results are provided by the analyzer if the Crea result, age, gender and ethnicity are available: eGFRAA (CKD-EPI) for African Americans (AA) and eGFR (CKD-EPI) for non-AA.

Crea (Creatinine), AG (Anion Gap), HCO3 (Bicarbonate), BUN/crea (BUN/Creatinine ratio) BEecf (Bace Excess of Extracellular Fluid (in vivo)), BE(B) (Base Excess of Blood (in vitro)), tHb(c) (Calculated Total Hemoglobin), Ca++ (7.4) (Ionized Calcium normalized to a pH of 7.4), Osm (Osmolality), eGFR (estimated Glomerular Filtration Rate), MDRD (Modification of Diet in Renal Disease), CKD-EPI (Chronic Kidney Disease - Epidemiology Collaboration)</div>
		<div>Configurable Assay Menu

</div>
		<div>Creatinine and eGFR</div>
		<div>Lab-Quality Results

Excellent concordance with plasma-calculated laboratory method1

Whole-blood samples tested on GEM Premier ChemSTAT system
demonstrated:98.3% of eGFR calculations were categorized in the correct risk
zone (n = 118)Equations used isotope dilution, mass spectrometry (IDMS)-traceable
MDRD and CKD-EPIIf patient’s race was unknown for eGFR calculations, concordance
evaluated as grouped whole blood vs plasma for
eGFR < or > 60 mL/min/1.73 m2Calculations performed for both AA and non-AA</div>
		<div>
</div>
		<div>
MDRD non-AAMDRD AA
ZONE A114 (96.6%)117 (99.2%)
ZONE B4 (3.4%)1 (0.8%)
ZONE C00
ZONE D00
</div>
		<div>Lab-Quality Results

eGFR Concordance: MDRD1

</div>
		<div>Error Grid Analysis</div>
		<div>Love SA, Schulz K, Stack P, et al. Clinical evaluation of a new point-of-care system for chemistry panel testing. J Appl Lab Med. 2019;4(2):180–92</div>
		<div>Lab-Quality Results

eGFR Concordance: CKD-EPI29

</div>
		<div>
CKD-EPI non-AA​CKD-EPI AA​
ZONE A116 (98.3%)116 (98.3%)
ZONE B2 (1.7%)2 (1.7%)
ZONE C00
ZONE D00
</div>
		<div>Performance Evaluation Using Error Grid Analysis1

Error Grid Analysis identifies impact of discordant results between whole blood
and plasma-calculated eGFRs
ZONE ACorrect risk classification – appropriate management
ZONE BIncorrect classification, but no implication for clinical management
ZONE CIncorrect classification, potential for unnecessary prophylaxis
or withholding of contrast
ZONE DIncorrect classification and potential for increased risk of
CIN due to insufficient prophylaxis
</div>
		<div>Snaith B, Harris MA, Shinkins B, et al. Point-of-care creatinine testing for kidney function measurement prior to contrast-enhanced diagnostic imaging; evaluation of the performance of three systems for clinical utility. Clin Chem Lab Med. 2018;56(8):1269–76.</div>
		<div>Creatinine and eGFR

Creatinine is an important marker of renal damageeGFR is an estimate of renal function (calculation of a patient’s blood Creatinine level, age, gender and race)Rapid, lab-quality creatinine and eGFR results enable clinicians to accurately assess renal function at the POC</div>
		<div>Simplifies and Centralizes POCT

Easy, at-a-glance dashboardOptimized interface for access from computer, tablet device or directly from GEM Premier ChemSTAT systemsWeb access from any browserReal-time remote management of analyzer configuration without testing interruptionTotal automated management of operators with multi-level authorization and traceability of users, actions and competenceSingle, unified database to access patient samples and historical resultsCentralized access to iQM data from multiple analyzersCustomizable to multiple connection types, including patient monitors, HIS/LIS and ADTOpen connectivity, including select non-IL analyzers** Contact your local representative for information on non-IL device connection details and availability.</div>
		<div>iQM
</div>

	</div>

	<!-- end text content: -->

  </body>
</html>
